# Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and Camlipixant

> **NCT05959447** · PHASE1 · COMPLETED · sponsor: **Bellus Health Inc. - a GSK company** · enrollment: 45 (actual)

## Conditions studied

- Cough
- Healthy

## Interventions

- **DRUG:** Camlipixant
- **DRUG:** Dabigatran etexilate
- **DRUG:** Gemfibrozil

## Key facts

- **NCT ID:** NCT05959447
- **Lead sponsor:** Bellus Health Inc. - a GSK company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-26
- **Primary completion:** 2023-10-13
- **Final completion:** 2023-10-13
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2025-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05959447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05959447, "Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and Camlipixant". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05959447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*